Dane Slentz, MD
Ophthalmology · Derry, NHNPI 1639580327
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,778 of the $126,633 with a category attached, or 74.8%. Amgen accounts for 97.3% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $39,867, more than ten times the $160 reported in 2019. Among ophthalmology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $453.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$123K
- ANI Pharmaceuticals, Inc.$707
- Biotissue Holdings Inc.$628
- Oyster Point Pharma, Inc.$279
- Genentech USA, Inc.$259
- Bausch & Lomb Americas Inc.$222
- plus $1K from 12 others
What the payments were for
- Consulting fees$8,5007%
- Speaking & faculty fees$94,77875%
- Travel & lodging$14,22611%
- Food & beverage$9,1057%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 194 | $123,244 |
| ANI Pharmaceuticals, Inc. | 14 | $707 |
| Biotissue Holdings Inc. | 12 | $628 |
| Oyster Point Pharma, Inc. | 11 | $279 |
| Genentech USA, Inc. | 3 | $259 |
| Bausch & Lomb Americas Inc. | 7 | $222 |
| Tarsus Pharmaceuticals, Inc. | 6 | $210 |
| Alcon | 3 | $202 |
| Sight Sciences, Inc. | 3 | $181 |
| Sun Pharmaceutical Industries Inc. | 10 | $156 |
| Rxsight Inc | 1 | $150 |
| AbbVie | 5 | $131 |
| Mallinckrodt Hospital Products Inc. | 3 | $105 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 1 | $33 |
| Glaukos Corporation | 1 | $24 |
| Alimera Sciences, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$111,018
- RXSIGHT CONTACT LENS$150
- RXSIGHT INJECTOR CARTRIDGE$150
- RXSIGHT INJECTOR HANDPIECE$150
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$150
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$150
- VABYSMO$144
- PURIFIED CORTROPHIN GEL$132
- Prokera$129
- AmnioGraft$129
- TEARCARE SYSTEM$113
- Rhopressa$112
- Rocklatan$112
- XDEMVY$107
How this compares
$126,633 in reported general payments places this provider in the 95th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $81,916 |
| RestasisCyclosporine | 25 | $39,168 |
| XiidraLifitegrast | 14 | $16,461 |
| CequaCyclosporine | 14 | $13,072 |
| Cyclosporine | 25 | $12,947 |
| ErythromycinErythromycin Base | 338 | $3,203 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 146 | $1,435 |
| Fluorometholone | 12 | $715 |
| Prednisolone Acetate | 16 | $516 |
| Latanoprost | 27 | $228 |
| Doxycycline Hyclate | 16 | $154 |
| Timolol Maleate | 17 | $148 |
| Triamcinolone Acetonide | 14 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $131 | $39,16825 claims |
| Bausch & Lomb Americas Inc.Xiidra | $222 | $16,46114 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $156 | $13,07214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Derry
- Mohamed GuenenaDerry$8K
- Gerald SpindelDerry$7K
- David VazanDerry$3K
- Jason SzelogPortsmouth$71K
- Andrew CatomerisLebanon$56K
- Jennifer LingPortsmouth$9K
- John DagianisNashua$9K
- Ahad FazelatManchester$8K
- Heather BartelsPeterborough$8K
- Thamolwan SurakiatchanukulLebanon$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.